Redeye is encouraged by the very strong Q4 numbers that beat our expectations on all accounts.
A very solid report, sales and EBIT in line A very solid report from G5 today.
Redeye takes a positive stance towards Hexatonic’s Q4 report.
Redeye shares its preview of Devyser Diagnostics’ Q4 2022 results, due on February 21.
Redeye comments on Mestro's agreement with Neobo Fastigheter worth SEK850,000 in subscription revenu...
Q4 results Q4 sales of SEK 4,687m (+2% vs. ABGSCe 4,596m), up 21% y-o-y.
15% organisk tillväxt… Marknaden är starkare än vad vi hade hoppats på och Transtema rapporterade or...
2022 var ett starkt år trots utmaningar och marginalpress Nettoomsättningen steg med 11% till 261 mk...
Redeye comments on Active Biotech's report for the fourth quarter and discusses events and the statu...
Fortsatt hög uthyrningsgrad och ökade driftöverskott Hyresintäkter i kvartalet uppgick till 8,5 mEUR...
Q4 report broadly in line '23 outlook somewhat soft, increased spending P/NAV of 0.
Reached '22 guidance, but disappointing '23 guidance Proposed DPS of DKK 4.
Disappointing GM, but 4% EBITDA beat on lower opex We lower '23e-'24e EBITDA by 2% Org.
CirChem publicerade den 7 februari bolagets delårsrapport för årets fjärde kvartal.
Q-linea has signed a new UK distribution partner in Canadian Pro-Lab Diagnostics.
Redeye comments on Annexin’s Q4 report, which came in as expected, and largely reiterate our view of...
Biovica’s US lab secures a CLIA certification following a successful site visit in January.
Raute reports Q4 results on Feb 14. There’s still haze around revenue and margins going forward, but...
Sales and adj. EBITDA -1% and +4% vs. ABGSCe -1,900 customer intake q-o-q vs.
Redeye gives a comment on Xavi Solutions Q4 2022 report that was revealed earlier today.
